Novel vaccines against M. tuberculosis

Kekkaku

Volumn 81, Issue 12, 2006, Pages 745-751

  Okada, Masaji ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Clinical application; Cynomolgus monkey; Cytotoxic T cells; HSP 65 DNA + IL 12 DNA vaccine; Recombinant BCG vaccine; TB vaccine

Indexed keywords

BCG VACCINE; DNA VACCINE; RECOMBINANT VACCINE;

ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DISEASE MODEL; HUMAN; IMMUNOLOGY; MACACA; MOUSE; MYCOBACTERIUM TUBERCULOSIS; REVIEW; T LYMPHOCYTE; TUBERCULOSIS;

ANIMALS; BCG VACCINE; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; MACACA FASCICULARIS; MICE; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 33847733558     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Okada M, Kita Y, Kanamaru N, et al.: Novel (recombinant BCG- and DNA-) vaccination against tuberculosis. Thirty- Seventh Tuberculosis and Leprosy Research Conference. 2002, 171-175.
2. Kita Y, Kanamaru N, Okada M, et al.: Novel recombinant BCG- and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine. 2005 ; 23 : k2269-2272.
3. Yoshida S, Kita Y, Okada M, et al.: DNA vaccine using hemagglutinating virus of Japan-liposorne encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine. 2006;24:1191-1204.
4. Miki K, Nagata T, Tanaka T, et al.: Induction of Protective Cellular Immunity against Mycobacterium tuberculosis by Recombinant Attenuated Self-Destructing Listeria Monocytogenes Strains Harboring Eukaryotic Expression Plasmids for Antigen 85 Complex and MPB/MPT51. Infection and Immunity. 2004;72:2014-2021.
5. Tanaka F, Abe M, Okada M, et al.: The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res. 1997;57:1335-1343.
6. Okada M, Takemoto Y, Okuno Y, et al.: The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. Vaccine. 2005;23:2269-2272.
7. McShane H, Huygen K, Hill A, et al.: Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG- primed and naturally acquired antimycobacterial immunity in humans. Nat Med. 2004 ; 10 (11) : 1240-1244.